Skip to Content

Adjuvant pembrolizumab for resected high-risk stage melanoma decreased the risk of death

In this MEDtalk Jason Luke, associate professor, presents the results from KEYNOTE-716 study, where patients with high-risk stage melanoma were treated with pembrolizumab (pembro) versus placebo in pts with resected AJCC-8 stage IIB or IIC melanoma

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top